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Abstract
Objectives:  outbreaks  of  sexually  transmitted  acute
HcV infection have been described recently in several
cities in the western world. the epidemic affects main-
ly MsM who are coinfected with HIV and is suppos-
ably linked to certain sexual risk practices. Here, we
compared  our  findings  with  current  knowledge  and
recommendations. 
Methods:  HIV-positive patients with the diagnosis of
acute HcV infection were included in the retrospec-
tive analysis. the patients came from outpatient infec-
tious disease centers in northern german cities. we
looked  at  markers  of  HIV  and  HcV  infection  and
compared patients who received treatment and those
who did not. treated patients were followed up to 72
weeks. 
Results: three  hundred  nineteen  HIV-positive  pa-
tients with the diagnosis of acute hepatitis c between
2001 and 2008 and were included in the analysis. All
patients were male, 315 (99%) patients were of cau-
casian  origin,  296  (93%)  declared  homosexual  con-
tacts as a risk factor for HcV infection, intravenous
drug use was declared in 3 (1%) cases. Median age at
HcV diagnosis was 40 years (range 20-69 years). Me-
dian HcV viral load was 1.2 x 106 Iu/ml, 222 pa-
tients (70%) had HcV genotype 1, 59 (18%) genotype
4. the median time of HIV infection was 5.5 years
(range 0 to 22.4 years). Median HIV viral load was
110 copies/ml (range 25 to 10x106 copies/ml). the
median  cd  4  count  was  461  cells/mm3 (range  55-
1331 cells/mm3). two hundred and fourty-six patients
(77%) received anti-HcV treatment, and 175 (55%)
had completed therapy by the time of the analysis.
Median treatment duration was 33 weeks (IQR 24.1-
49.9). 93 of the 175 treated patients (53%) reached a
sustained virological response (sVR). In the multivari-
ate  analysis,  ARt  at  diagnosis,  HcV  RnA  drop  at
week 12, hemoglobin levels and higher platelets were
associated with sVR. treatment duration was signifi-
cantly higher in the sVR group (40.6 weeks vs 26.6
weeks,  p<0.0001).  seventy-three  patients  (23%)  did
not receive anti-HcV treatment. In 19 of the untreat-
ed  patients  (26%)  the  hepatitis  c  virus  was  cleared
spontaneously.
Conclusions: our findings confirm that acute hepatitis
c in HIV infected patients affects mainly MsM who
acquire HcV sexually. Patients hadashort duration of
HIV infection and a stable immunological situation. In
this  real-life  setting  from  urban  regions  in  northern
germany, treatment rates appear to be high and effec-
tive.
Key  words: Acute hepatitis c, HIV, interferon, sVR,
spontaneous clearance
IntRoductIon
An outbreak of sexually transmitted acute hepatitis c
virus (HcV) infection has been documented in large
cities in Europe, the united states and Australia dur-
ing the past years [1-7]. the epidemic, that mainly af-
fects  men  who  have  sex  with  men  (MsM)  who  are
coinfected  with  the  human  immunodeficiency  virus
(HIV), seems to be linked to a certain sexual risk be-
havior within parts of the homosexual community and
is suspected to be spread through a “sexual network”
of men frequenting the same clubs and “sex parties”
in different urban regions of the world. whereas the
transmission of HcV in this part of the world has
been  historically  associated  with  parenteral  infection
such as intravenous drug use in the majority of cases,
permucosal trauma seems to be the main risk factor in
these “new” patients [8, 9]. 
since the introduction of combination antiretrovi-
ral  therapy  (cARt)  has  substantially  prolonged  sur-
vival [10], liver disease such as chronic hepatitis c is
one of the major factors for mortality and morbidity
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assumed sexual spread of HcV may have a serious
clinical impact for HIV positive MsM.
HIV coinfection seems to lead to a lower rate of
spontaneous clearance in acute HcV infection, a faster
fibrosis progression in chronic hepatitis c and reduces
response  rates  to  standard  treatment  regimens  with
pegylated  interferon  (PegIfn)  and  Ribavirin  (RBV)
[12-15] compared to the HcV monoinfected popula-
tion.
several  groups  from  England,  france,  germany,
Australia, the united states and the netherlands have
recently published their data on the nature of the epi-
demic  and  treatment  outcomes  in  HIV-acute  HcV-
coinfected  patients.  sustained  virological  response
rates in these studies ranged between 59 and 80% of
the treated patients, depending on genotype and treat-
ment duration [16]. Interestingly, the results from an
observational European multicentre cohort showed no
influence  of  HcV  genotype  or  HcV  viral  load  on
overall sVR rates of 62% [17]. several issues such as
the type of pegylated interferon used, a benefit of ad-
ditional  ribavirin  or  the  optimal  starting  point  for
treatment  and  treatment  duration  remain  still  un-
solved. However, prospective trials have unfortunately
not yet been undertaken and are urgently needed to
answer these questions.
the aim of this retrospective analysis was to review
treatment decisions and outcomes in HIV positive pa-
tients with acute hepatitis c in a routine clinical set-
ting.  Moreover,  we  tried  to  compare  these  findings
with current knowledge and recommendations.
PAtIEnts And MEtHods
consecutive patients coinfected with HIV and acute
hepatitis c were included in this retrospective analysis.
the patients came from outpatient infectious disease
centers in northern german cities. these centers care
for approximately 9000 HIV positive patients annual-
ly, of whom about 1350 (15%) are HcV co-infected.
Acute  hepatitis  c  was  defined  as  a  positive  HcV 
polymerase  chain  reaction  (PcR),  and  at  least  two
conditions  out  of  the  following  being  confirmed:
HcV seroconversion within the last 6 months, an in-
crease in serum Alt of more than 350 Iu/ml or a
suspected risk event in the past 6 months before diag-
nosis.
data was collected by chart review. we looked at
demographic factors, risk factors for HcV infection,
HcV viral load and HIV surrogate markers as well as
liver function tests at the time of diagnosis of acute
HcV infection. the history of HIV infection, the cur-
rent treatment for HIV infection, and the number of
patients in stage c3 according to the classification of
the centre for disease control (cdc, Atlanta, usA)
[18] was taken into account.
furthermore,  the  physician´s  clinical  impression
(symptomatic, asymptomatic) at the time of diagnosis
of acute HcV was included in the analysis.
the patients were then divided into two groups, a
treated group and an untreated group. treated patients
received at least one dose of either pegylated interfer-
on α-2a (180µg per week subcutaneously (s.c.)) or pe-
gylated  interferon  α-2b  (1.5mg/kg  body  weight  per
week s.c.) with or without weight-based ribavirin (800-
1200mg/d).
treated patients were followed with the same labo-
ratory markers mentioned above at week 4, 12, 24 and
48 of treatment and during a 24-week follow up peri-
od after the last dose of interferon to define sVR. un-
treated patients were followed up to observe sponta-
neous clearance.
laboratory  parameters  were  measured  locally.
HcV-PcR  was  performed  with  ultrasensitive  assays
with a lower limit of quantification (llQ) between 15
Iu/ml and 600 Iu/ml, as detection limits changed
over the time of the observation period.
statistical analysis was performed using “R” (the R
foundation  for  statistical  computing,  Vienna,  Aus-
tria). student´s t-test was used to compare groups, a p-
value below 5% was considered statistically significant.
A multivariate analysis by logistic regression was con-
ducted to define the odd‘s ratios of sVR.
REsults
A total of three hundred nineteen HIV-positive pa-
tients met the criteria for acute hepatitis c between
2001 and 2008 and were included in the analysis. Pa-
tients came from ten different ambulatory care centers
in 4 different cities in germany, however, 264 patients
(83%)  were  diagnosed  in  Berlin.  All  patients  were
male, 315 (99%) patients were of caucasian origin, 296
(93%) declared homosexual contacts as the only possi-
ble  risk  factor  for  HcV  infection,  intravenous  drug
use was declared in 3 (1%) cases and for 21 patients
EuRoPEAn JouRnAl of MEdIcAl REsEARcH 238 May 12, 2011
Table 1. Baseline characteristics of the 319 HIV patients with
acute hepatitis ca.
Age [years] (range) 40 (20-69)
Sex, male [%] 100
HCV transmission risk MSM, n (%) 296 (93)
Time since HIV infection [years] 5.5 (0-22.4)
(range)
CD4 count [cells/µl] (range) 461 (55-1331)
HIV viral load [copies/mL] (range) 110 (50-10x106)
cART, n (%) 200 (63)
CDC stage C, n (%) 59 (18)
HCV RNA [IU/mL] (range) 1.2x106 (33-676x106)
HCV genotype 1, n (%) 222 (70)
Maximum ALT level at diagnosisb 420 (19-4217)
[IU/mL] (range)
Symptomatic hepatitis, as indicated  83 (26)
by physician, n (%)
Time to treatmentc, weeks (IQR) 12.6 (4.7-24.4)
Duration of therapy, weeks (IQR) 33 (24.1-49.9)
avalues are given as median unless otherwise indicated.
bMaximum  median  alanin  aminotransferase  (Alt)  level  is
the maximum increase in Alt measured at the time of dia  -
gnosis. 
ctime to treatment is the time between diagnosis and first
dose given. MsM, men who have sex with men. cdc, center
for disease control and prevention.
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diagnosis was 40 years (range 20-69 years).
Median HcV viral load was 1.2 x 106 Iu/ml. the
HcV  genotype  distribution  was  as  follows:  222  pa-
tients (70%) had genotype 1, 7 (2%) genotype 2, 26
(8%) genotype 3, 59 (18%) genotype 4, and in 5 (2%)
patients  the  HcV  genotype  was  not  indicated.  the
median maximum alanin aminotransferse (Alt) level
at diagnosis was 420 Iu/ml (range 19 to 4217). the
median  bilirubin  level  was  1.2  mg/dl  (range  0.1  to
35).  In  83  cases  (26%)  patients  were  indicated  as
symptomatic by their physician.
the median time of HIV infection was 5.5 years
(range 0 to 22.4 years). two hundred patients (63%)
were on cARt or started cARt at the time of HcV
diagnosis, 26 patients had a history of antiretroviral
therapy  but  were  currently  not  treated,  79  patients
were naϊve for HIV therapy, and in 13 cases no data
on HIV treatment could be retrieved. overall, 105 pa-
tients (33%) were not treated for HIV infection. 59
(18%) patients were classified as cdc stage c3, in 4
cases this information was not available. Patients on
cARt did not differ from untreated patients in terms
of Alt levels, bilirubin levels, absolute cd 4 lympho-
cyte  count.  HcV  viral  load  was  higher  in  the  non-
cARt group (1.8 x 106 iu/ml vs 1.0 x 106 iu/ml).
Median HIV viral load was 110 copies/ml (range
25 to 10x106 copies/ml). the median cd 4 lympho-
cyte  count  was  461  cells/mm3 (range  55-1331
cells/mm3), median cd4 percentage was 24% (range 3
to  64).  Baseline  characteristics  are  summarized  in
table 1. 
two hundred and fourty-six patients (77%) received
anti-HcV  treatment,  and  175  (55%)  had  completed
therapy by the time of the analysis. All treated patients
received either pegylated interferon α-2a or α-2b, 240
patients (91% of treated patients) received additional
ribavirin. 
the  median  time  from  diagnosis  to  initiation  of
treatment  was  12.6  weeks  (IQR  4.7-24.4).  Median
treatment duration was 33 weeks (IQR 24.1-49.9). 93
of the 175 treated patients (53%) met the sVR criteria
(HcV viral load undetectable 24 weeks after end of
therapy), 42 (24%) did not and in another 40 patients
the follow-up period was not yet terminated or data
was missing. In the on-treatment analysis, 69% of the
patients fulfilled the criteria for sVR. sVR was associ-
ated with an earlier onset of anti-HcV treatment after
diagnosis (9.6 weeks vs 11 weeks), but this was not sta-
tistically significant. In multiple logistic regression a vi-
ral load drop at week 12, drop in hemoglobin levels at
week  12,  higher  platelets  and  cARt  at  the  time  of
HcV  diagnosis  turned  out  statistically  significant
(table  2).  A  rapid  virological  response  (RVR,  HcV
RnA undetectable at week 4) was reached in 31% of
patients. RVR predicted sVR in 87%. At week 12, 108
patients had undetectable HcV RnA (early virological
response  -  EVR)  and  70  patients  (65%)  reached  an
sVR. of the 38 patients that did not fulfill the criteri-
on of an EVR, only 6 (15%) finally had an sVR.treat-
ment  duration  was  significantly  higher  in  the  sVR
group (40.6 weeks vs 26.6 weeks, p<0.0001). More-
over, we saw a trend towards lower HcV PcR levels at
diagnosis and the achievement of sVR, however, this
difference was not significant. no difference was seen
in maximum gPt levels before treatment between pa-
tients with or without sVR.
treatment was interrupted before week 24 in 30 pa-
tients, in 15 cases due to non-response or virological
breakthrough, in the other cases due to side effects.
seventy-three patients (23%) did not receive anti-HcV
treatment. In 19 of the untreated patients (26%) the
hepatitis c virus was cleared spontaneously. the medi-
an cd4 cell count in these patients was 461/mm3, me-
dian bilirubin was 2.15 mg/dl (p=0.03) and the medi-
an gPt level was 744 Iu/ml. In untreated patients
without spontaneous clearance the median gPt level
was  339  Iu/ml  and  the  median  bilirubin  level  was
1mg/dl. these differences were not statistically sig-
nificant.
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Table 2. Multiple logistic regression of factors associated with sVR.
p value Odds-Ratio CI 2,5 CI 97,5
HCV RNA week 0 0.1151 1.00 1.00 1.00
HCV-RNA decline week 4 0.1767 2.11 0.83 8.99
HCV-RNA decline week 12 0.0178 2.85 1.35 8.38
ALT max b 0.2786 1.00 1.00 1.01
Hb week 0 a 0.07 0.20 0.02 0.79
Hb week 4 0.1665 0.46 0.13 1.28
Hb week 12 0.024 4.71 1.44 23.30
HIV viral load week 0 0.8572 1.00 1.00 1.00
ALT week 0 0.8024 1.00 0.99 1.00
GGT week 0 0.8421 1.00 0.99 1.01
Platelets week 0 0.0337 0.96 0.91 0.99
ART vs no ART at diagnosis 0.0338 3.94 2.83 9.84
CD4 cell count week 0 0.2988 1.00 1.00 1.01
aweek refers to anti-HcV treatment week, bMaximum median alanin aminotransferase (Alt) level is the maximum increase in
Alt measured at the time of diagnosis. Hb, hemoglobin, ARt, antiretroviral treatment 
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this retrospective analysis could give an interesting in-
sight on the “real life” management of acute hepatitis
c in HIV coinfected patients. our patients were main-
ly middle-aged men and nearly all of them indicated
homosexual contacts as the assumed risk factor for ac-
quiring HcV. this goes in line with the findings of
other work groups dealing with the same issue [5, 18-
20]. All of our patients were diagnosed in german ur-
ban areas with Berlin appearing to be the hotspot of
transmission.
our patients were HIV-positive and had a relatively
stable  immunological  situation  with  a  median  cd4
count at 461 cells/mm3 and no more than 9 patients
had a cd4 count below 200 cells/mm3 at the time of
hepatitis c diagnosis. only 18% of our patients had a
history of an AIds-defining event. Moreover, the me-
dian time of HIV infection was relatively low (about 5
years). this confirms findings from other cohorts [17]
and one may conclude that an impaired immune sys-
tem is not a necessary risk factor to acquire hepatitis c
sexually.  Although  it  has  been  postulated  that  HIV
coinfection might facilitate HcV transmission by in-
creasing  both  viral  infectiousness  because  of  higher
HcV viral loads in serum and semen and viral suscep-
tibility  through  impaired  immunologic  control  of
HcV [20, 21] no proof of this concept has yet been
found. this leads to the thesis that behavioral risk fac-
tors such as “serosorting sex parties” and traumatic
sexual practices are necessary for the sexual transmis-
sion [9]. Moreover, rare cases of sexual HcV trans-
mission  in  HIV  negative  MsM  have  been  described
[22]. It is noteworthy that HIV infected patients are
more likely to be diagnosed with concomitant diseases
due to regular medical check-ups, which is also true
for the diagnosis of hepatitis c. However, in several
cohorts it has been shown recently that acute sexually
transmitted hepatitis c rarely occurs in HIV-negative
individuals and also not in HIV-infected women [23-
26].
About one third of our patients was not treated for
their HIV infection and several patients started HIV
treatment when diagnosed with acute HcV infection.
considering the fact that HcV was acquired by risky
sexual behavior, it is even more alarming that these
persons have replicative HIV disease and therefore a
high chance of transmission.
seventy-seven percent of our patients received anti-
HcV treatment. this is highly promising as similar co-
horts in chronically co-infected patients showed con-
siderably  low  rates  of  treatment  initiation  [27]  al-
though HIV coinfection has the potential to aggravate
HcV disease progression [12]. this is even more im-
portant as liver-related death has become the most fre-
quent cause of non–AIds-related death in the HIV
infected population, mainly due to hepatitis c virus
coinfection [28].
we found high rates of sVR in our cohort. with
69% in the on-treatment analysis sVR rates were clear-
ly higher than in chronically co-infected patients, al-
though most of our patients had unfavourable geno-
types 1 and 4. this has also been described by other
groups and the sVR rates are in concordance with the
rates  found  in  several  European  cohorts  [17].Viral
load drop at week 12, drop in hemoglobin levels at
week  12,  higher  platelets  and  cARt  at  the  time  of
HcV diagnosis were significantly associated with sVR.
Most of the treated patients included in this analy-
sis received additional ribavirin (91%) to their treat-
ment  with  pegylated  interferon.  An  impact  of  this
combination on treatment outcome can therefore not
be drawn from these data. It rather shows that physi-
cians stick to approved regimens in clinical practice as
ribavirin  is  part  of  the  standard-of-care  in  chronic
HcV infection. However, the use of ribavirin for the
treatment of acute hepatitis c has been an issue of
discussion. In acute HcV monoinfection high rates of
sVR have been reached with interferon or pegylated
interferon monotherapy [29-31]. In most of the trials
on  coinfected  patients  additional  ribavirin  had  been
used, but in the german cohort patients treated with
pegylated interferon alone achieved higher sVR rates
than  patients  on  pegylated  interferon  and  ribavirin
combination therapy, although the difference in sVR
was not statistically significant and the number of pa-
tients was low [32]. Matthews et al. described compa-
rable  response  rates  in  coinfected  patients  from  the
Australian cohort when treated with PEg/RBV com-
pared  to  monoinfected  treated  with  PEg  alone
[32].the median time from diagnosis to treatment ini-
tiation was 12.6 weeks. this implies that a part of the
patients were treated late regarding the course of acute
HcV infection. some of our patients were rather to
be  classified  as  early  chronic  than  as  late  acute.  of
note, our data come from a retrospective analysis and
not from a prospective trial. Patients in this analysis
were included since 2001, and knowledge and treat-
ment decisions changed over time. this analysis rather
reflects  acute  hepatitis  c  under  real-life  conditions.
Accordingly,  patients  that  were  treated  earlier  had
higher rates of sVR. 
we found a high rate of spontaneous clearance in
the  untreated  patients  group  (26%).  this  confirms
findings from a pooled analysis of several European
cohorts [33]. However, HIV infection has been associ-
ated with high rates of HcV persistence, which, it has
been hypothesized, is related to its impact on cellular
immune function [34]. this was confirmed by danta
et al. who found that 95% of HIV-acute HcV coin-
fected  patients  developed  persistent  HcV  infection
[35].  the  few  patients  that  cleared  HcV  infection
spontaneously  had  significantly  higher  Alt  levels,
were icteric and had higher cd4 cell counts. In our
cohort, bilirubin and Alt levels were higher in pa-
tients who cleared HcV, and cd4 count was identical
to  the  overall  cohort,  but  no  statistical  significance
could have been found. A real estimation of the spon-
taneous clearance rate in the natural course of HcV
infection cannot be drawn from a dataset like ours.to
date,  clear-cut  criteria  for  the  likelihood  of  sponta-
neous clearance are not known. Most experts recom-
mend to determine the drop of HcV RnA at week 4.
If HcV RnA has dropped for 2 log or more, observa-
tion for spontaneous clearance might be reasonable in
4-weeks intervals up to week 12. However, delaying
the start of treatment for too long may eradicate the
benefit of early treatment [16].In conclusion, our data
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7) Baumgarten_Umbruchvorlage  21.04.11  15:26  Seite 240describes  the  largest  cohort  of  acute  HcV  infected
patients so far. It is able to prove what has been postu-
lated  by  several  workgroups  concerning  the  demo-
graphics and treatment outcomes in acute HcV and
HIV coinfection. Especially in the setting of HIV in-
fection, the physicians‘ awareness is needed to preco-
ciously spot HcV infections as early treatment leads to
better results.
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